03 June 2015
Privately-held Switzerland-headquartered Ferring Pharmaceuticals has signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
“We are glad to collaborate with NovaMedica and believe that this company is the right choice because of its long-term strategy targeted at bringing innovative gastroenterological products to Russian patients”
The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices.
Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024